Zobrazeno 1 - 10
of 290
pro vyhledávání: '"Ulrik Lassen"'
Autor:
Annie Borch, Ibel Carri, Birkir Reynisson, Heli M. Garcia Alvarez, Kamilla K. Munk, Alessandro Montemurro, Nikolaj Pagh Kristensen, Siri A. Tvingsholm, Jeppe Sejerø Holm, Christina Heeke, Keith Henry Moss, Ulla Kring Hansen, Anna-Lisa Schaap-Johansen, Frederik Otzen Bagger, Vinicius Araujo Barbosa de Lima, Kristoffer S. Rohrberg, Samuel A. Funt, Marco Donia, Inge Marie Svane, Ulrik Lassen, Carolina Barra, Morten Nielsen, Sine Reker Hadrup
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundMutation-derived neoantigens are critical targets for tumor rejection in cancer immunotherapy, and better tools for neoepitope identification and prediction are needed to improve neoepitope targeting strategies. Computational tools have ena
Externí odkaz:
https://doaj.org/article/0bbbca7628154c30a577b6a43214db8d
Autor:
Tina Kringelbach, Martin Højgaard, Kristoffer Rohrberg, Iben Spanggaard, Britt Elmedal Laursen, Morten Ladekarl, Charlotte Aaquist Haslund, Laurine Harsløf, Laila Belcaid, Julie Gehl, Lise Søndergaard, Rikke Løvendahl Eefsen, Karin Holmskov Hansen, Annette Raskov Kodahl, Lars Henrik Jensen, Marianne Ingerslev Holt, Trine Heide Oellegaard, Christina Westmose Yde, Lise Barlebo Ahlborn, Ulrik Lassen
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background An increasing number of trials indicate that treatment outcomes in cancer patients with metastatic disease are improved when targeted treatments are matched with druggable genomic alterations in individual patients (pts). An estim
Externí odkaz:
https://doaj.org/article/904750a8228c462b9f8145bcff4832b1
Autor:
Annie Borch, Anne-Mette Bjerregaard, Vinicius Araujo Barbosa de Lima, Olga Østrup, Christina Westmose Yde, Aron Charles Eklund, Morten Mau-Sørensen, Carolina Barra, Inge Marie Svane, Finn Cilius Nielsen, Samuel A. Funt, Ulrik Lassen, Sine Reker Hadrup
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Immune checkpoint inhibition for the treatment of cancer has provided a breakthrough in oncology, and several new checkpoint inhibition pathways are currently being investigated regarding their potential to provide additional clinical benefit. Howeve
Externí odkaz:
https://doaj.org/article/0b564ce2af7e487693f9954c485f26ea
Autor:
Dorte Schou Nørøxe, Aidan Flynn, Christina Westmose Yde, Olga Østrup, Finn Cilius Nielsen, Jane Skjøth‐Rasmussen, Jannick Brennum, Petra Hamerlik, Joachim Weischenfeldt, Hans Skovgaard Poulsen, Ulrik Lassen
Publikováno v:
Molecular Oncology, Vol 16, Iss 1, Pp 206-218 (2022)
Treatment of glioblastoma (GBM) remains a challenging task, with limited treatment options, none offering a cure. Immune therapy has proven effective across different cancers with remarkable response rates. Tumor mutational burden (TMB) is a marker o
Externí odkaz:
https://doaj.org/article/f11ab63d8fd145b89bc5de41725aeb19
Autor:
Vladimir Lazar, Jacques Raynaud, Shai Magidi, Catherine Bresson, Jean-François Martini, Susan Galbraith, Fanny Wunder, Amir Onn, Gerald Batist, Nicolas Girard, Ulrik Lassen, C. S. Pramesh, Amal Al-Omari, Sadakatsu Ikeda, Guy Berchem, Jean-Yves Blay, Benjamin Solomon, Enriqueta Felip, Josep Tabernero, Eitan Rubin, Thierry Philip, Angel Porgador, Ioana Berindan-Neagoe, Richard L. Schilsky, Razelle Kurzrock
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: SARS-CoV-2 (COVID-19) elicits a T-cell antigen-mediated immune response of variable efficacy. To understand this variability, we explored transcriptomic expression of angiotensin-converting enzyme 2 ( ACE2 , the SARS-CoV-2 receptor) and o
Externí odkaz:
https://doaj.org/article/cacbf20affbf406896e87fc22d539ae7
Autor:
Dorte S. Nørøxe, Christina W. Yde, Olga Østrup, Signe R. Michaelsen, Ane Y. Schmidt, Savvas Kinalis, Mathias H. Torp, Jane Skjøth‐Rasmussen, Jannick Brennum, Petra Hamerlik, Hans S. Poulsen, Finn C. Nielsen, Ulrik Lassen
Publikováno v:
Molecular Oncology, Vol 14, Iss 11, Pp 2727-2743 (2020)
Glioblastoma (GBM) is an incurable brain tumor for which new treatment strategies are urgently needed. Next‐generation sequencing of GBM has most often been performed retrospectively and on archival tissue from both diagnostic and relapse surgeries
Externí odkaz:
https://doaj.org/article/d0baf8c1908b4eccb7b839bb49a9e326
Autor:
Mette Brøgger-Mikkelsen, John Robert Zibert, Anders Daniel Andersen, Ulrik Lassen, Merete Hædersdal, Zarqa Ali, Simon Francis Thomsen
Publikováno v:
PLoS ONE, Vol 17, Iss 7, p e0271819 (2022)
BackgroundIncreasing costs and complexity in clinical trials requires recruitment of more narrowly defined patient populations. However, recruitment for clinical trials remains a considerable challenge.AimOur overall aim was to quantify recruitment p
Externí odkaz:
https://doaj.org/article/116eb2d48e8b495c892a34b0795caa76
Autor:
Thomas Urup, Linn Gillberg, Katja Kaastrup, Maya Jeje Schuang Lü, Signe Regner Michaelsen, Vibeke Andrée Larsen, Ib Jarle Christensen, Helle Broholm, Ulrik Lassen, Kirsten Grønbæk, Hans Skovgaard Poulsen
Publikováno v:
Molecular Oncology, Vol 14, Iss 5, Pp 964-973 (2020)
Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because
Externí odkaz:
https://doaj.org/article/a869f372b7954f5c8bf9715dcc5ecaf3
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-12 (2019)
Abstract Background Knowledge of what the pharmaceutical industry emphasizes when assessing trial sites during site selection is sparse. A better understanding of this issue can improve the collaboration on clinical trials and increase knowledge of h
Externí odkaz:
https://doaj.org/article/fd3d43d665d94a568d237275ef92c98d
Autor:
Vinicius Araujo B. de Lima, Morten Hansen, Iben Spanggaard, Kristoffer Rohrberg, Sine Reker Hadrup, Ulrik Lassen, Inge Marie Svane
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Despite encouraging results with immune checkpoint inhibition (ICI), a large fraction of cancer patients still does not achieve clinical benefit. Finding predictive markers in the complexity of the tumor microenvironment is a challenging task and oft
Externí odkaz:
https://doaj.org/article/288c3e1e8d1b4ed49ef9c80d21b72006